Cannabinoids for the pharmaceutical industry

Euphytica

Volumn 140, Issue 1-2, 2004, Pages 83-93

  Stott, Colin G ^a   Guy, Geoffrey W ^a  

^a Porton Down Science Park   (United Kingdom)

Author keywords

Cannabidiol; Cannabinoids; Cannabis sativa L.; Delta 9 tetrahydrocannabinol; Endocannabinoids; Sativex

Indexed keywords

EID: 16444374071     PISSN: 00142336     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10681-004-4757-8     Document Type: Conference Paper

References (39)

1. Aldrich, M.R., 1997. History of therapeutic cannabis. In: M.L. Mathre (Ed.), Cannabis in Medical Practice: A Legal, Historical and Pharmacological Overview of the Therapeutic Use of Marijuana. McFarland.
2. Berman, J., J. Lee, A. Cannon, J. Sach, S. Tripp, S. McKerral, M. Taggart, C.P. Symonds, K. Fisher & R. Birch, 2004. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomized controlled trial. PAIN 112(3): 299-306.
3. Brady, C.M., R. DasGupta, C. Dalton, O.J. Wiseman, K.J. Berkley & C.J. Fowler, 2004. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis 10: 425-433.
4. Browne, R.G. & A. Weissman, 1981. Discriminative stimulus properties of delta-9-tetrahydrocannabinol: Mechanistic studies. J Clin Pharmacol 21 (8-9 Suppl): 227S-234S.
5. Carlini, E.A., I.G. Karniol, P.F. Renault & C.R. Schuster, 1974. Effects of marihuana in laboratory animals and man. Br J Pharmacol 50: 299-309.
6. Devane, W.A., F.A. Dysarz 3rd, M.R. Johnson, L.S. Melvin & A.C. Howlett, 1988. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34(5): 605-613.
7. Devane, W.A., L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger & R. Mechoulam, 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258(5090): 1946-1949.
8. Elphick, M. & M.R. Ergetova, 2001. The neurobiology and evolution of cannabinoid signalling. Phil Trans R Soc Lond Ser B Biol Sci 356(1407): 381-408.
9. Fairbairn, J.W. & J.T. Pickens, 1981. Activity of cannabis in relation to its delta-1-trans-tetrahydro-cannabinol content. Br J Pharmacol 72: 401-409.
10. Food & Drug Administration, 2004. Guidance for Industry: Botanical Drug Products. Drug Information Branch (HFD-210), Center for Drug Evaluation and Research (CDER), FDA, Rockville, MD 20857, USA.
11. Freund, T.F., I. Katona & D. Piomelli, 2003. Role of endogenous cannabinoids in synaptic signalling. Physiol Rev 83(3): 1017-1066.
12. Gaoni, Y. & R. Mechoulam, 1964. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647.
13. Grinspoon, L. & J.B. Bakalar, 1993. Marihuana, the Forbidden Medicine. Yale University Press, New Haven.
14. Grinspoon, L. & J.B. Bakalar, 1997. Marihuana, the forbidden medicine, revised edition. Yale University Press, New Haven.
15. Hanus, L., S. Abu-Lafi, E. Fride, A. Breuer, Z. Vogel, D.E. Shalev, I. Kustanovich & R. Mechoulam, 2001. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98(7): 3662-3665.
16. Howlett, A.C. & M.R. Fleming, 1984. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26(3): 532-538.
17. Howlett, A.C., 1984. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35 (17): 1803-1810.
18. Huang, S.M., T. Bisogno, M. Trevisani, A. Al-Hayani, De L. Petrocellis, F. Fezza, M. Tognetto, T.J. Petros, J.F. Krey, C.J. Chu, J.D. Miller, S.N. Davies, P. Geppetti, J.M. Walker, Di V. Marzo, 2002. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99(12): 8400-8405.
19. Matsuda, L.A., S.J. Lolait, M.J. Brownstein, A.C. Young & T.I. Bonner, 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284): 561-564.
20. McPartland, J. & E.B. Russo, 2001. Cannabis and cannabis extracts: Greater than the sum of their parts? J Cannabis Ther 1(3-4): 103-132.
21. McPartland, J., 2003. Neurobiological effects of cannabinoids. American Academy of Pain Management (AAPM), Lecture, 4 September 2003.
22. Mechoulam, R., Z.A. Ben-Zvi, H. Shani Zemler & S. Levy, 1972. Cannabinoids and cannabis activity. In: W.D.M. Paton & J. Crown (Eds.), Cannabis and its Derivatives, pp. 1-13. Oxford University Press, London.
23. Munro, S., K.L. Thomas, M. Abu-Shaar, 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441): 61-65.
24. Notcutt, W., M. Price, R. Miller, S. Newport, C. Phillips, S. Simmons & C. Sansom, 2004. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34′ N of 1′ studies. Anaesthesia 59(5): 440-452.
25. 2 receptors. Pharmacol Ther 74(2): 129-180.
26. Pertwee, R.G., 2004. The pharmacology and therapeutic potential of cannabidiol. In: V. Di Marzo (Ed.), Cannabinoids. Kluwer Academic/Plenum Publishers.
27. Porter, A.C., J.M. Sauer, M.D. Knierman, G.W. Becker, M.J. Berna, J. Bao, G.G. Nomikos, P. Carter, F.P. Bymaster, A.B. Leese & C.C. Felder, 2002. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301(3): 1020-1024.
28. Potter, D.J., 2004. Growth and morphology of medicinal cannabis. In: G.W. Guy, B.A. Whittle & P.J. Robson (Eds.), The Medicinal Uses of Cannabis and Cannabinoids. Pharmaceutical Press, London.
29. Robson, P.J., 2001. The therapeutic uses of cannabis. Abstracts of the 17th Association of Nurses in Substance Abuse (ANSA) UK National Conference, April 2001.
30. Rog, D.J. & C.A. Young, 2003. Randomised controlled trial of cannabis based medicinal extracts in central neuropathic pain due to multiple sclerosis. Abstracts of the 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (September 17-20, Milan, Italy).
31. Russo, E.B. & J. McPartland, 2003. Cannabis is more than simply delta-9-tetrahydrocannabinol. Psychopharmacology 165: 431-432.
32. Russo, E.B., 2001. Hemp for headache: An in-depth historical and scientific review of cannabis in migraine treatment. J Cannabis Ther 1(2): 21-92.
33. Russo, E.B., 2002. Cannabis treatments in obstetrics and gynaecology: A historical review. J Cannabis Ther 2(3-4): 5-35.
34. Serpell, M., E. Smith & N. Sarantis, Sativex in the treatment of pain of neurological origin or symptoms of Multiple Sclerosis: Interim analysis of a long-term, open lable, safety and tolerability study. Abstracts of the 8th Congress of EFNS, 04-07 September 2004, Paris, France.
35. Sharief, M.K., 2004. Sativex® in the treatment of patients with chronic refractory pain due to MS or other defects of neurological function. Abstracts of the Spring Scientific Meeting of the Association of British Neurologists, 14-16 April, London, UK.
36. The House of Lords Science and Technology Committee, 1998. Ninth Report. "Cannabis: The Scientific Evidence". HMG The Stationery Office.
37. Wade, D.T., P. Makela, P.J. Robson, H. House & C. Bateman, 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo controlled study on 160 patients. Multiple Sclerosis 10: 434-441.
38. Wade, D.T., P.J. Robson, H. House, P. Makela & J. Aram, 2002. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17: 21-29.
39. Walton, R.P., 1938. Marihuana, America's New Drug Problem. Philadelphia, J.B. Lippincott Co.